26rhk217 10.3205/26rhk217 urn:nbn:de:0183-26rhk2170 Meeting Abstract Berg Berg Laura L

Universitätsklinikum Schleswig-Holstein, Klinik für Rheumatologie und klinische Immunologie, Lübeck, Deutschland

author Graßhoff Graßhoff Hanna H

Universitätsklinikum Schleswig-Holstein, Klinik für Rheumatologie und klinische Immunologie, Lübeck, Deutschland

author Gedik Gedik Handan H

Universitätsklinikum Schleswig-Holstein, Institut für Entzündungsmedizin, Lübeck, Deutschland

author Zirpel Zirpel Henner H

Universitätsklinikum Schleswig-Holstein, Institut für Entzündungsmedizin, Lübeck, Deutschland

author Spallek Spallek Elisabeth E

Universitätsklinikum Schleswig-Holstein, Institut für Entzündungsmedizin, Lübeck, Deutschland

author Ha-Wissel Ha-Wissel Linh L

Universität zu Lübeck, Institut für Experimentelle Dermatologie, Lübeck, Deutschland

author Heidecke Heidecke Harald H

CellTrend GmbH, Luckenwalde, Deutschland

author Schulze-Forster Schulze-Forster Kai K

CellTrend GmbH, Luckenwalde, Deutschland

author Lamprecht Lamprecht Peter P

Universitätsklinikum Schleswig-Holstein, Klinik für Rheumatologie und klinische Immunologie, Lübeck, Deutschland

author Thaci Thaci Diamant D

Universitätsklinikum Schleswig-Holstein, Institut für Entzündungsmedizin, Lübeck, Deutschland

author Riemekasten Riemekasten Gabriela G

Universitätsklinikum Schleswig-Holstein, Klinik für Rheumatologie und klinische Immunologie, Lübeck, Deutschland

author German Medical Science GMS Publishing House

Düsseldorf

610 20260909 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0656 217 Deutsche Gesellschaft für Rheumatologie Deutsche Gesellschaft für Orthopädische Rheumatologie Gesellschaft für Kinder- und Jugendrheumatologie 54. Kongress der Deutschen Gesellschaft für Rheumatologie und Klinische Immunologie (DGRh), 36. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR), 40. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh) Deutscher Rheumatologiekongress 2026 Spondyloarthritiden Leipzig 20260909 20260912 SpA.08 TextIntroduction: Fatigue is a common and burdensome symptom in Psoriatic Arthritis (PsA), characterized by reduced physical and cognitive performance . It has a multifactorial origin and arises from inflammatory processes, disease symptoms, sleep disturbances, or psychological comorbidities . Besides these, recent data suggest a role of autoantibodies (abs) targeting G-protein coupled receptors (GPCR) in fatigue in Post-COVID syndrome . Here, we aimed to characterize fatigue in PsA and to investigate its association with clinical parameters and GPCR abs.Methods: Patients (n = 115) with active PsA were treated with either csDMARDs or biologics in accordance with GRAPPA recommendations. Over a 12-month period following treatment initiation, fatigue was assessed at seven time points using the FACIT-Fatigue questionnaire. In parallel, patients underwent in-depth clinical characterization. Levels of GPCR abs were measured by CellTrend GmbH (Germany).Results: At baseline, patients showed a high disease activity, with a DAPSA score of 32.4 ± 23.6. In the FACIT-Fatigue questionnaire, 43.4% of patients reported severe fatigue, defined as a score < 30. Using Wilcoxon matched-pairs signed rank test, a significant reduction in fatigue scores was observed after 4 weeks (p=0.0202), 16 weeks (p=0.0118), 24 weeks (p=0.0168), 40 weeks (p=0.0008), and 52 weeks (p=0.0024) compared to baseline.K-means clustering of FACIT-Fatigue scores at weeks 0, 2, 4, and 16 identified four clusters. One cluster, comprising 30.9% of patients, demonstrated an improvement in fatigue under immunosuppressive treatment. Comparison of therapeutics between clusters revealed no significant differences. Similarly, no significant differences were found between clusters regarding achievement of minimal disease activity criteria.Multinomial regression analysis using GPCR abs as predictors of cluster assignment revealed a potential association with abs targeting angiotensin II type 1 receptor (p=0.029), muscarinic receptor 2 (p=0.043), adrenergic receptors α1 (p=0.010) and α2 (p=0.030), and protease-activated receptor 1 (p=0.029).Conclusion: This study demonstrates that fatigue is highly prevalent and relevant in PsA. As only 30.9% of patients experienced a significant improvement in FACIT-Fatigue questionnaire with immunosuppressive treatment, the presented data suggest that fatigue is influenced by factors beyond inflammatory disease activity. These data support for the first time a role of GPCR Abs in fatigue in autoimmune diseases.Disclosures: Nothing to declare. Nymand L Kristensen LE Thomsen SF Thyssen JP Egeberg A Characteristics and drivers of fatigue in patients with psoriasis and psoriatic arthritis: A cross sectional study 2024 J Am Acad Dermatol 57-63 Nymand L, Kristensen LE, Thomsen SF, Thyssen JP, Egeberg A. Characteristics and drivers of fatigue in patients with psoriasis and psoriatic arthritis: A cross sectional study. J Am Acad Dermatol. 2024 Jul;91(1):57-63. DOI: 10.1016/j.jaad.2024.02.026 http://dx.doi.org/10.1016/j.jaad.2024.02.026 Zielinski MR Systrom DM Rose NR Fatigue, Sleep, and Autoimmune and Related Disorders 2019 Front Immunol 1827 Zielinski MR, Systrom DM, Rose NR. Fatigue, Sleep, and Autoimmune and Related Disorders. Front Immunol. 2019 Aug 6;10:1827. DOI: 10.3389/fimmu.2019.01827 http://dx.doi.org/10.3389/fimmu.2019.01827 Sotzny F Filgueiras IS Kedor C Freitag H Wittke K Bauer S Sepúlveda N Mathias da Fonseca DL Baiocchi GC Marques AHC Kim M Lange T Plaça DR Luebber F Paulus FM De Vito R Jurisica I Schulze-Forster K Paul F Bellmann-Strobl J Rust R Hoppmann U Shoenfeld Y Riemekasten G Heidecke H Cabral-Marques O Scheibenbogen C Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity 2022 Front Immunol 981532 Sotzny F, Filgueiras IS, Kedor C, Freitag H, Wittke K, Bauer S, Sepúlveda N, Mathias da Fonseca DL, Baiocchi GC, Marques AHC, Kim M, Lange T, Plaça DR, Luebber F, Paulus FM, De Vito R, Jurisica I, Schulze-Forster K, Paul F, Bellmann-Strobl J, Rust R, Hoppmann U, Shoenfeld Y, Riemekasten G, Heidecke H, Cabral-Marques O, Scheibenbogen C. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front Immunol. 2022 Sep 27;13:981532. DOI: 10.3389/fimmu.2022.981532 http://dx.doi.org/10.3389/fimmu.2022.981532 0 0 0 0